Inclusion Criteria:
- Must be ≥18 years of age at the time of consent
- Must be able to provide written informed consent personally or by legally authorized
representative
- Must have 1 of the following histologically confirmed Non-Hodgkin Lymphoma (NHL)
subtypes:
- Diffuse large B-cell lymphoma (DLBCL), NOS; or DLBCL high-grade lymphoma, not
otherwise specified (NOS); or DLBCL high-grade B-cell lymphoma with MYC and BCL2
and/or BCL6 rearrangements with DLBCL histology (double/triple-hit lymphoma)
- Epstein-Barr virus-positive or composite DLBCL are allowed
- Follicular lymphoma (FL)
- Must have been previously treated with ≥ 1 prior systemic therapy (e.g., chemotherapy,
immunotherapy, or chemoimmunotherapy)
- For first relapsed/refractory (R/R) DLBCL cohort, participant must have confirmed R/R
disease within 90 days prior to study enrollment and must intend to initiate 2L
systemic treatment
- For first R/R FL cohort, participant must have confirmed R/R disease (grade 1 to 3B or
transformed) within 90 days prior to study enrollment and must intend to initiate 2L
systemic treatment
- Participant must be willing and able to complete enrollment and follow-up
health-related quality of life (HRQoL) and social support instruments
- Participants volunteering for the Tissue Sub-Study must consent for use of their
blood/tumor biopsies, which were collected as per standard of care, for exploratory
analyses
Exclusion Criteria:
- Participant whose prior start and end date of DLBCL or FL treatment, and prior
treatment received, including chemotherapy, radiation, surgery (not including
excisional biopsies), and other anticancer therapy, are unknown
- Participant who has any other active malignancy (non-DLBCL or non-FL) for which the
participant is receiving treatment at the time of enrollment or any other former
malignancy that was diagnosed within 6 months prior to Registry enrollment (with the
exception of non-melanoma skin cancer)
- Currently enrolled in any interventional clinical trial where the participant is being
treated with an investigational product that cannot be identified
Recruiting
